H1N1sw Vaccine in Adult Transplant Recipients

This study has been terminated.
(End of H1N1 Swine Flu Pandemic)
Sponsor:
Information provided by (Responsible Party):
HepNet Study House, German Liverfoundation
ClinicalTrials.gov Identifier:
NCT01069601
First received: February 15, 2010
Last updated: April 13, 2012
Last verified: April 2012
  Purpose

The trial investigates the efficacy of the adjuvanted H1N1 influenza vaccine Focetria(R) in immunocompromised adults who have undergone solid organ or bone marrow transplantation. It is expected that when administered twice the vaccine fulfills all serological efficacy criteria required for the elderly population age 60 years and older.


Condition Intervention Phase
Immunocompromised
Biological: Focetria (2x H1N1 vaccine with MF59 adjuvants)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by HepNet Study House, German Liverfoundation:

Primary Outcome Measures:
  • The adjuvanted H1N1 influenza vaccine, when administered twice in transplanted patients, fulfils all serological efficacy criteria as required for the elderly population (aged 60 and older) according to the respective European guidance documents. [ Time Frame: 42 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The adjuvanted H1N1 influenza vaccine in transplanted patients, when administered twice, is at least as effective as the adjuvanted H1N1 influenza vaccine in the healthy volunteers after only one administration. [ Time Frame: 42 days ] [ Designated as safety issue: Yes ]

Enrollment: 13
Study Start Date: February 2010
Study Completion Date: April 2012
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: transplanted adults
male and female adults who have previously undergone solid organ transplantation or allogeneic or autologous BMT
Biological: Focetria (2x H1N1 vaccine with MF59 adjuvants)
7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
Other Name: Focetria(R)

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adult subjects 18-60 years of age who have undergone prior renal, cardiac, liver, lung, or bone marrow transplantation for any reason, more than 3 months prior to enrolment
  • Patients able to visit the outpatient clinic with a life expectancy of at least one year
  • Patients who receive any immunosuppressive treatment currently taken to prevent organ rejection

Exclusion Criteria:

  • Individuals who received any vaccine within 30 days prior to study entry
  • Individuals who received a H1N1 vaccination less than 6 months prior to the study
  • Influenza diagnosed by a physician within 4 months prior to the study start
  • Pregnant or lactating females
  • History of an anaphylactic (i.e. life-threatening) reaction to any of the components of the vaccines, including egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01069601

Locations
Germany
Hannover Medical School
Hannover, Germany, 30655
Sponsors and Collaborators
HepNet Study House, German Liverfoundation
Investigators
Principal Investigator: Michael P Manns, Prof Hannover Medical School
  More Information

No publications provided

Responsible Party: HepNet Study House, German Liverfoundation
ClinicalTrials.gov Identifier: NCT01069601     History of Changes
Other Study ID Numbers: 2009-017052-27, 200910H1N1MHH
Study First Received: February 15, 2010
Last Updated: April 13, 2012
Health Authority: Germany: Federal Agency for Sera and Vaccines

Keywords provided by HepNet Study House, German Liverfoundation:
solid organ transplantation
bone marrow transplantation
adults
adults with solid organ transplantation
adults with bone marrow transplantation

ClinicalTrials.gov processed this record on October 30, 2014